Evidence map›Paper›PMID 19822292›Full record

ReviewSeminars in thoracic and cardiovascular surgery2009

Making the case for molecular staging of malignant pleural mesothelioma.

Raphael Bueno

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in thoracic and cardiovascular surgery, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Malignant pleural mesothelioma: predictors and staging.Annals of translational medicine · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Raphael BuenoDivision of Thoracic Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. Rbueno@partners.org

Funding

Validation of Prognostic and Diagnostic Molecular Tests in MesotheliomaR01CA120528 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BUENO, RAPHAEL · 2006 to 2021
$4.8M
Gene Ratio Based Prognosis in MesotheliomaR33CA100315 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BUENO, RAPHAEL · 2005 to 2007
$1.0M
NCI NIH HHS R01 CA120528NCI NIH HHS R33 CA100315
6 · The paper itself

Abstract

Malignant pleural mesothelioma is an aggressive malignancy for which surgical treatment is an option for a subset of patients. A gene ratio test based on the relative expression levels of four genes has been validated in clinical trials to predict which patients will benefit from surgical therapy. A description of the test properties and the independent predictors for outcome are provided.

Indexed as

Molecular Diagnostic TechniquesBiomarkers, TumorBiopsyGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMesotheliomaNeoplasm StagingPatient SelectionPleural NeoplasmsPredictive Value of TestsReproducibility of ResultsRisk AssessmentThoracic Surgical ProceduresTreatment OutcomeBiomarkers, Tumor

Identifiers

PMID19822292
PMCPMC2904964

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.